Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea
ConclusionsDiscrepancies in dapagliflozin eligibility were observed between real-world data and clinical trial results. The addition of dapagliflozin to HF therapy proved to be highly cost-effective across the entire EF spectrum.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Dapagliflozin | European Medicines Agency (EMA) | Forxiga | Heart | Heart Failure | South Korea Health | Study